Functional genomics resources for the Drosophila and broader research communities

项目概要-总体 我们将在现有的基础设施、专业知识和跟踪记录的基础上建立果蝇研究中心， 筛选中心-生物医学技术研究资源（DRSC-BTRR）。我们的总体目标是帮助 研究人员认识到果蝇作为人类健康和疾病研究模型的全部潜力， 作为医学相关昆虫的模型，例如传染病的蚊子媒介。DRSC-BTRR将 在三个技术领域开发最先进的工具和方法：（1）开发功能基因组学 用于果蝇细胞和体内研究的技术（包括CRISPR-Cas9技术）;（2） 将功能基因组和蛋白质组技术应用于人类疾病的蚊子载体;以及（3） 果蝇体内蛋白质组学技术的发展。我们将通过以下方式开发技术： 一轮又一轮的开发、测试和改进，以及一系列推动生物医学项目 可以从这些技术的应用中受益。为了进一步扩大技术的影响，我们将 参与社群活动，向广大受众提供信息，并迅速向其他人传播技术 设施，以确保长期使用。总之，我们将作为一个综合的，协作的资源， 参与在几个NIH研究所感兴趣的领域具有强大影响潜力的项目， 包括基础细胞和有机体生物学、发育生物学、癌症治疗学、罕见遗传学、 疾病和蚊子传播的疾病。

PROJECT SUMMARY – OVERALL We will build on our existing infrastructure, expertise, and track-record to form the Drosophila Research and Screening Center-Biomedical Technology Research Resource (DRSC-BTRR). Our overall goal will be to help researchers realize the full potential of Drosophila as a model for the study of human health and disease, and as a model of medically-relevant insects such as mosquito vectors of infectious disease. The DRSC-BTRR will develop state-of-the-art tools and methods in three technology areas: (1) development of functional genomics technologies for Drosophila cell-based and in vivo studies (including CRISPR-Cas9 technologies); (2) application of functional genomic and proteomic technologies to mosquito vectors of human diseases; and (3) development of in vivo proteomics technologies for Drosophila. We will develop the technologies through iterative rounds of development, testing, and improvement together with a set of driving biomedical projects that can benefit from application of the technologies. To further extend the impact of the technologies, we will engage in community activities that inform a broad audience and rapidly disseminate technologies to other facilities to ensure long-term access. Altogether, we will serve as an integrated, collaborative resource engaging in projects with strong potential for impact in areas that are of interest to several NIH institutes, including fundamental cell and organismal biology, developmental biology, cancer therapeutics, rare genetic disorders, and mosquito-borne diseases.